Tucatinib

{
  "id": "MLC-T-ONC-008947",
  "term": "Tucatinib",
  "field": "Oncology and biomedicine",
  "definitions": [
    "A drug used with other drugs to treat adults with certain types of HER2-positive breast cancer or certain types of HER2-positive colorectal cancer that do not have a mutation (change) in the RAS gene. It is also being studied in the treatment of other types of cancer. Tucatinib blocks a protein called HER2, which may help keep cancer cells from growing and may kill them. It is a type of tyrosine kinase inhibitor. Also called Tukysa.",
    "An orally bioavailable inhibitor of the human epidermal growth factor receptor tyrosine kinase ErbB-2 (also called HER2) with potential antineoplastic activity. Tucatinib selectively binds to and inhibits the phosphorylation of ErbB-2, which may prevent the activation of ErbB-2 signal transduction pathways, resulting in growth inhibition and death of ErbB-2-expressing tumor cells. ErbB-2 is overexpressed in a variety of cancers and plays an important role in cellular proliferation and differentiation."
  ],
  "synonyms": [
    "Tukysa",
    "irbinitinib",
    "ONT-380"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms",
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/tucatinib/"
}